JP2023539390A5 - - Google Patents

Info

Publication number
JP2023539390A5
JP2023539390A5 JP2023537445A JP2023537445A JP2023539390A5 JP 2023539390 A5 JP2023539390 A5 JP 2023539390A5 JP 2023537445 A JP2023537445 A JP 2023537445A JP 2023537445 A JP2023537445 A JP 2023537445A JP 2023539390 A5 JP2023539390 A5 JP 2023539390A5
Authority
JP
Japan
Prior art keywords
group
alkyl
compound according
acyl
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539390A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2021/051214 external-priority patent/WO2022047583A1/en
Publication of JP2023539390A publication Critical patent/JP2023539390A/ja
Publication of JP2023539390A5 publication Critical patent/JP2023539390A5/ja
Pending legal-status Critical Current

Links

JP2023537445A 2020-09-02 2021-09-02 ニトロ化サイロシビン誘導体ならびに5-ht2a受容体を調節するためおよび精神障害を処置するためのその使用 Pending JP2023539390A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073534P 2020-09-02 2020-09-02
US63/073,534 2020-09-02
PCT/CA2021/051214 WO2022047583A1 (en) 2020-09-02 2021-09-02 Nitrated psilocybin derivatives and use thereof for modulating 5-ht2a receptor and for treating a psychiatric disorder

Publications (2)

Publication Number Publication Date
JP2023539390A JP2023539390A (ja) 2023-09-13
JP2023539390A5 true JP2023539390A5 (https=) 2024-09-04

Family

ID=80492288

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537445A Pending JP2023539390A (ja) 2020-09-02 2021-09-02 ニトロ化サイロシビン誘導体ならびに5-ht2a受容体を調節するためおよび精神障害を処置するためのその使用

Country Status (10)

Country Link
US (1) US20230040398A1 (https=)
EP (1) EP4208446A4 (https=)
JP (1) JP2023539390A (https=)
KR (1) KR20230061473A (https=)
CN (1) CN116782896A (https=)
AU (1) AU2021336667A1 (https=)
CA (1) CA3191095A1 (https=)
IL (1) IL301028A (https=)
MX (1) MX2023002619A (https=)
WO (1) WO2022047583A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3152752A1 (en) 2019-10-01 2021-04-08 Thomas Henley Genetic engineering of fungi to modulate tryptamine expression
KR20230157342A (ko) 2021-02-12 2023-11-16 인베릭 바이오사이언시스 캐나다 인크. 다중 치환기 실로시빈 유도체 및 사용 방법
CN118984868A (zh) 2021-12-31 2024-11-19 恩派瑞安神经科学公司 用于产生精神药物生物碱的遗传修饰的生物体
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2023173196A1 (en) 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
AU2023234202A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. Salts of c4-carboxylic acid- and c4-carbonothioate-substituted tryptamine derivatives and methods of using
AU2023382178A1 (en) * 2022-11-18 2025-06-05 Enveric Biosciences Canada Inc. Substituted n-propylamine fused heterocyclic mescaline derivatives

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4425399A (en) * 1998-06-08 1999-12-30 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
KR20030046395A (ko) * 2000-07-28 2003-06-12 인스파이어 파마슈티컬스 인코퍼레이티드 인돌 유도체를 사용하여 안압을 감소시키는 방법
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
DK1859798T3 (en) * 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
EP1747779A1 (en) * 2005-07-28 2007-01-31 Laboratorios Del Dr. Esteve, S.A. Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands
CN103601662B (zh) * 2013-11-21 2016-04-06 深圳市药品检验所 一种褪黑素半抗原、褪黑素完全抗原及其制备方法和应用
EP3119406B1 (en) * 2014-03-18 2021-01-20 Carmel-Haifa University Economic Corporation Ltd Methods for improving cognitive function via modulation of quinone reductase 2
US11078467B2 (en) * 2016-10-26 2021-08-03 University Of Florida Research Foundation, Incorporated Highly active self-sufficient nitration biocatalysts
US11261157B2 (en) * 2016-12-08 2022-03-01 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
US20200147038A1 (en) * 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US10640508B2 (en) * 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers

Similar Documents

Publication Publication Date Title
JP2023539390A5 (https=)
JP2023539949A5 (https=)
JP2024512154A5 (https=)
JP2020517707A5 (https=)
JP2021534124A5 (https=)
JP2021514001A5 (https=)
JP2010501003A5 (https=)
JP2011520815A5 (https=)
JP2021523200A5 (https=)
MX2014001549A (es) Hemifumarato de tenofovir alafenamida.
JP2021517126A5 (https=)
US9040498B2 (en) 1,2,3-Triazolyl purine derivatives
JP2006505543A5 (https=)
GB1601020A (en) 2'-deoxy-5 (2-halogenovinyl)-uridines
JP2024539946A5 (https=)
JP2023002701A5 (https=)
JP2021523169A5 (https=)
JP2025502943A5 (https=)
JP2024545787A5 (https=)
JP2022541545A5 (https=)
JP2025507292A5 (https=)
JP2025507915A5 (https=)
JP2024506667A5 (https=)
JPH05509307A (ja) プリンの抗ウイルス性ホスホノ―アルケン誘導体
JP2014519507A5 (https=)